SAN FRANCISCO–(BUSINESS WIRE)–Today, VeriSIM Life (VeriSIM) broadcasts the launch of its pharmaceutical subsidiary, PulmoSIM Therapeutics (PulmoSIM) with the mission to handle the unmet wants within the therapy of uncommon respiratory ailments, with an instantaneous emphasis on pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF).
PulmoSIM is growing breakthrough therapies for uncommon and progressive respiratory ailments to enhance affected person outcomes and high quality of life. PulmoSIM’s method modulates a number of organic pathways with a single agent, thus assuaging the necessity of mixture therapies. With repurposing and repositioning already authorized FDA medicine, PulmoSIM is concentrating on the underlying biology to successfully deal with PAH and IPF.
“We are thrilled to announce the launch of PulmoSIM as it demonstrates the indefinite capabilities of the VeriSIM’s platform, BIOiSIM, in accelerating drug development by bridging the translational gap between preclinical and clinical phases. In contrast to working with pharmaceutical and biotech companies in developing their drug portfolios, the PulmoSIM launch will be the first of many assets we will be developing to solve the most challenging and unaddressed diseases impacting human-kind”, mentioned Dr. Jo Varshney.
“Out of >7,000 rare diseases, many exist in hard-to-reach peripheral regions of the respiratory system. PulmoSIM aims to leverage the immense potential drug repurposing has to offer, to tackle at least a few of these rare diseases. Development of affordable, and commercially feasible therapies is one of the many ways to improve quality of life and compliance among the patients suffering from these indications”, mentioned the Scientific Founder, Dr. Vivek Gupta.
PulmoSIM can also be happy to announce the institution of its Scientific Advisory Board: Dr. Eva S. Nozik, MD (Professor, Pediatrics-Critical Care Medicine, School of Medicine, University of Colorado, Denver, CO), Dr. Samir Mitragotri, PhD (Hiller Professor of Bioengineering and Wyss Professor of Biologically Inspired Engineering, Harvard University, Boston, MA), and Dr. Hugh Smyth, PhD (Alcon Centennial Professor of Molecular Pharmaceutics and Drug Delivery, University of Texas, Austin, TX).
“Unlike current approaches that seek symptomatic relief, PulmoSIM’s approach is novel as it targets the biology of the disease. Targeting the underlying disease mechanisms opens the path to effective and life-saving therapies”, mentioned Dr. Samir Mitragotri.
The launch of PulmoSIM is an thrilling enterprise for VeriSIM, and is the subsequent part in leveraging their first-in-class synthetic intelligence platform to predict the medical efficacy of medicine and propel drug improvement innovation ahead. The PulmoSIM group is well-versed in respiratory ailments, product improvement, and has the expertise, experience, and relationships to effectively handle additional operational, medical, regulatory, aggressive, and monetary dangers as we propel to medical proof-of-concept. To study extra about our pipeline, method, and the way we will accomplice – contact us at: [email protected]
About VeriSIM Life: VeriSIM is redefining the method to preclinical and medical drug improvement with an AI enabled platform that delivers bio-simulations and predicts the medical outcomes of medicine earlier than human trials. Our method mannequin is constructed to precisely translate, scale, and speed up improvement; derisking R&D choices and enabling pharmaceutical and biotech organizations with the insights to propel innovation ahead. With our first-in-class, proprietary AI-enabled platform our group of scientists, modelers, chemists, and software program engineers are your companions on a mission to advance human well being.
About Dr. Jyotika Varshney: Dr. Jo Varshney, DVM, PhD in comparative oncology/genomics, is the founder and CEO of VeriSIM and its wholly-owned subsidiary, PulmoSIM. She is a visionary within the area of personalised illness fashions and synthetic intelligence/machine studying led drug improvement. She is the inventor of the core expertise that makes use of a singular method of integrating AI/ML methods into the modeling paradigm to improve the scalability and safety to superior software program techniques and may capitalize or seize the early drug improvement market. Dr. Varshney is a dynamic and celebrated chief and moreover, she serves on a number of advisory boards to assist different deep-tech firms commercialize their science and expertise.
About Dr. Vivek Gupta: Dr. Vivek Gupta, PhD, is the scientific founding father of PulmoSIM. Dr Gupta has 14+ years of expertise in growing localized therapies for uncommon respiratory ailments together with PAH and IPF. He additionally serves as an Assistant Professor of Pharmaceutical Sciences at St. John’s University, NY, the place his analysis group focuses on novel drug discovery and supply for respiratory issues.